<DOC>
	<DOCNO>NCT02483312</DOCNO>
	<brief_summary>This phase 1 study ( first stage test new treatment see safe tolerable treatment ) include patient acute myeloid leukemia ( AML ) either return 70 % chance come back bone marrow transplant . This study see whether modify patient 's AML cell produce IL-12 give back patient safe useful patient AML bone marrow transplant .</brief_summary>
	<brief_title>A Study ( Interleukin-12 ) IL-12 Patients With Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Patient AML &gt; =18 year age . Agrees participate study sign inform consent Viably freeze cell time diagnosis relapse available First complete remission high risk feature relapse . Less 10 % blast cell bone marrow follow induction reinduction therapy desire intensive treatment . Acceptable creatinine , Aspartate transaminase ( AST ) , Alkaline phosphatase ( ALP ) , bilirubin Agree use contraception Not pregnant Able comply study procedure Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Known persistent infection Known central nervous system ( CNS ) disease Greater 10 % blast bone marrow circulate blast cell Life expectancy &lt; 2 month Receiving chemotherapy , corticosteroid , Cox2 inhibitor nondrug therapy intent alter immune response kill leukemic cell within one week prior infusion IL12 infect cell .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Recurrent</keyword>
</DOC>